Caplacizumab for congenital thrombotic thrombocytopenic purpura

Am J Hematol. 2022 Nov;97(11):E420-E421. doi: 10.1002/ajh.26693. Epub 2022 Sep 8.

Abstract

Caplacizumab rapidly increased platelet count which likely shorted the hospital stay and reduced plasma transfusion requirement.

Publication types

  • Letter

MeSH terms

  • ADAMTS13 Protein
  • Blood Component Transfusion
  • Humans
  • Plasma
  • Plasma Exchange
  • Purpura, Thrombotic Thrombocytopenic* / drug therapy
  • Single-Domain Antibodies
  • von Willebrand Factor

Substances

  • Single-Domain Antibodies
  • von Willebrand Factor
  • caplacizumab
  • ADAMTS13 Protein